Project Grant R21HD113986

Award Date 4/10/25
Completion Date 3/31/27
Dollars Obligated $254K
Federal Grant Program
93.865
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
This $504,283 federal Project Grant was awarded by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865). The grant will fund a prospective cohort study examining the etiology of autism spectrum disorder (ASD) in children born preterm compared to term-born children. The study aims to: 1) Determine the epidemiology of ASD in preterm children and identify associated risk factors; 2) Estimate...
This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $756,565.44 to the University of California, Los Angeles (UCLA) to conduct research on functional analysis of histone modifier autism spectrum disorders risk genes in vertebrate development. The award period runs from August 1, 2024 to July 31, 2027. The research efforts under this grant aim to...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to develop a new therapeutic approach for neurodevelopmental mitochondrial disorders. The $105,625 award, provided from August 2024 to July 2026, will support research to analyze the metabolism of a specific succinyl-CoA precursor in a mouse model of pyruvate dehydrogenase...
This Project Grant award from the National Institute of Mental Health (NIMH) under CFDA Program 93.242 - Mental Health Research Grants will provide $388,800 to support research on the cognitive and psychopathological profiles of individuals with autism spectrum disorder (ASD) who carry genetic variants associated with both ASD and schizophrenia (SCZ). The key products and services to be delivered under this award include: Remote assessment of cognition and psychopathology in 400 participants...
This $272,125 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to investigate the feasibility of genetically targeted therapies for epigenetic neurodevelopmental disorders. The project aims to develop enabling mouse transgenic reagents and conduct proof-of-principle studies to assess the tractability of reinstating expression...
This National Institute of Mental Health (NIMH) Project Grant under the Mental Health Research Grants program (CFDA 93.242) will provide $194,940 in funding from July 1, 2024 to June 30, 2028 to support a research program led by Dr. Mo at Boston Children's Hospital. The goal is to study the role of somatic (post-zygotic) genetic variants in the risk and mechanisms of autism spectrum disorder (ASD). The project will utilize a combination of whole exome sequencing, ATAC-seq, whole genome...
This R01 Project Grant, awarded by the National Institute of Mental Health (NIMH) under CFDA 93.242 Mental Health Research Grants, is funding a $1,854,632 research study at the Children's Hospital of Philadelphia (CHOP) from July 2024 to January 2027. The project aims to investigate the links between mitochondrial dysfunction, synaptic impairment, and the development of schizophrenia. Specifically, the researchers will study mitochondrial biogenesis, mitophagy, and glutamatergic synaptic release...
This Project Grant award of $443,121 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to study dysregulated protein synthesis and translation in an autism spectrum disorder (ASD) model. The project aims to leverage innovative in situ cryo-electron microscopy (cryo-EM) techniques to analyze the localization, activity, and structure of FMRP...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $251,250 to conduct research on the sex-dependent dysregulation of parvalbumin interneurons as a pathway to Autism Spectrum Disorder (ASD). The research aims to determine whether the reduction in parvalbumin-expressing interneurons observed in the hippocampus of male mice exposed in utero to anti-CASPR2 antibodies is associated with epigenetic...
This $499,055.48 federal Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) supports research to identify novel noncoding mechanisms of disease associated with developmental disorders (DDs). The key objectives are to: (1) define novel candidate long-range positional effect loci by identifying topologically associated domains (TADs) intolerant to disruption and building models to predict...

This federal Project Grant award of $253,500.00 from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to resolve the relationship between mitochondrial dysfunction and the impact of non-syndromic autism spectrum disorder (ASD)-related risk genes on neuronal structure and function.

The key products or services to be delivered through this grant include: (1) establishing "two-hit" human induced pluripotent stem cell (hiPSC) lines presenting with impaired neuronal bioenergetics caused by mitochondrial DNA heteroplasmy and deficiency in ASD-relevant risk genes (PPP2R5D, SHANK3, or GRIN2B); (2) imaging these "two-hit" hiPSC-derived neurons and 3D brain organoids to reconstruct neurons and neuronal networks, quantify soma size and dendritic morphology, and assess synapse number; and (3) delineating neuronal network-level phenotypes when expressing disease-associated ASD risk variants in neurons with suboptimal mitochondrial function. The award period is from April 10, 2025 to March 31, 2027.

Generated 4/29/25, 4:48 AM